Previous Close | 1.1500 |
Open | 1.2100 |
Bid | 1.1700 x 3200 |
Ask | 1.2500 x 1800 |
Day's Range | 1.1700 - 1.2100 |
52 Week Range | 0.6840 - 2.8650 |
Volume | |
Avg. Volume | 922,390 |
Market Cap | 271.374M |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3220 |
Earnings Date | Aug 10, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.58 |
Subscribe to Yahoo Finance Plus to view Fair Value for OTLK
Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ISELIN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced its financial results for its fiscal third quarter ended June 30, 2022, pr
ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17. In addition to the presenta
We feel now is a pretty good time to analyse Outlook Therapeutics, Inc.'s ( NASDAQ:OTLK ) business as it appears the...